DHE

Global and China Hybrid Electric Vehicle (HEV) Research Report 2023-2024: Dedicated Hybrid Engines (DHE) with Thermal Efficiency of 45% have been Mass-Produced, and Industrial Upgrade is Imminent - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
EV, Electric Vehicles, Green Technology, Environment, Automotive, IAA, DHT, Bev, GM, BYD, Great Wall of China, BEV, Li Auto, Original equipment manufacturer, Volkswagen, Research, Anxiety, Ford, BorgWarner, Carbon, Geely, ICE, HEM, Research report, HEV, Dongfeng, GAC, DHE, PHEV, REEV, Electric motor

The "Global and China Hybrid Electric Vehicle (HEV) Research Report, 2023-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and China Hybrid Electric Vehicle (HEV) Research Report, 2023-2024" report has been added to ResearchAndMarkets.com's offering.
  • As new models continue to emerge, the sales of plug-in/extended-range hybrid electric passenger cars will be on the rise.
  • It is expected that by 2025, plug-in/extended-range hybrid electric passenger cars will take up 40% of the new energy passenger car sales in China.
  • Dedicated hybrid engines (DHE) with thermal efficiency of 45% have been mass-produced, and industrial upgrade is imminent.

Global and China Hybrid Electric Vehicle (HEV) Research Report 2023-2024: In 2025, the Share of Plug-in/Extended-range Hybrid Electric Passenger Cars by Sales in China is Expected to Rise to 40%

Retrieved on: 
Friday, March 15, 2024
IAA, DHT, Bev, GM, BYD, Great Wall of China, BEV, Li Auto, Original equipment manufacturer, Volkswagen, Research, Anxiety, Ford, BorgWarner, Carbon, Geely, ICE, HEM, Research report, HEV, Dongfeng, GAC, DHE, PHEV, REEV, Electric motor

DUBLIN, March 15, 2024 /PRNewswire/ -- The "Global and China Hybrid Electric Vehicle (HEV) Research Report, 2023-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2024 /PRNewswire/ -- The "Global and China Hybrid Electric Vehicle (HEV) Research Report, 2023-2024" report has been added to ResearchAndMarkets.com's offering.
  • In China, plug-in/extended-range hybrid electric passenger cars already make up 30.6% of new energy passenger cars.
  • As new models continue to emerge, the sales of plug-in/extended-range hybrid electric passenger cars will be on the rise.
  • It is expected that by 2025, plug-in/extended-range hybrid electric passenger cars will take up 40% of the new energy passenger car sales in China.

Quantum Communications Technology Upgrades Are Essential to Protect Our High-Value Data, Reports IDTechEx

Retrieved on: 
Thursday, January 25, 2024
Hardware, PCI Express, PRNG, Physics, Agile management, QKD, Pressure, Communication, Data, Software, TRNG, PQC, Quantum, DHE, Comparison, QRNG, Telecommunications, Gambling, Growth, Microscope

The new IDTechEx quantum communication market report, " Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts ", simplifies this complex technology into accessible to read terms and separates the hype from the reality as to its disruptive potential.

Key Points: 
  • The new IDTechEx quantum communication market report, " Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts ", simplifies this complex technology into accessible to read terms and separates the hype from the reality as to its disruptive potential.
  • The first wave of technology to disrupt the communications market is post quantum cryptography.
  • "Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts" contextualizes QKD within the larger cryptography industry shifts, and identifies the key technology approaches and leading companies within the quantum communication market.
  • "Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts" provides critical market intelligence about quantum communication market.

Quantum Communications Technology Upgrades Are Essential to Protect Our High-Value Data, Reports IDTechEx

Retrieved on: 
Thursday, January 25, 2024
Hardware, PCI Express, PRNG, Physics, Agile management, QKD, Pressure, Communication, Data, Software, TRNG, PQC, Quantum, DHE, Comparison, QRNG, Telecommunications, Gambling, Growth, Microscope

The new IDTechEx quantum communication market report, " Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts ", simplifies this complex technology into accessible to read terms and separates the hype from the reality as to its disruptive potential.

Key Points: 
  • The new IDTechEx quantum communication market report, " Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts ", simplifies this complex technology into accessible to read terms and separates the hype from the reality as to its disruptive potential.
  • The first wave of technology to disrupt the communications market is post quantum cryptography.
  • "Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts" contextualizes QKD within the larger cryptography industry shifts, and identifies the key technology approaches and leading companies within the quantum communication market.
  • "Quantum Communication Market 2024-2034: Technology, Trends, Players, Forecasts" provides critical market intelligence about quantum communication market.

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Retrieved on: 
Tuesday, September 19, 2023
Multicenter trial, User experience, IV, Efficacy, Acute, Pharmacokinetics, Sympathetic nervous system, DHE, Randomness, Dihydroergotamine, Evaluation, FDA, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Tolerability, Safety, Migraine

BEDFORD, Mass., Sept. 19, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine. The PUR3100 formulation uses Pulmatrix's novel, proprietary dry powder delivery technology, iSPERSE™ to deliver DHE via oral inhalation using a dry powder inhaler.

Key Points: 
  • The PUR3100 formulation uses Pulmatrix's novel, proprietary dry powder delivery technology, iSPERSE™ to deliver DHE via oral inhalation using a dry powder inhaler.
  • Dr. Margaret Wasilewski, Chief Medical Officer of Pulmatrix noted, "We are pleased with the PUR3100 IND acceptance and receipt of the study may proceed letter for the Phase 2, proof of concept study.
  • The completed Phase 1 study demonstrated optimal pharmacokinetics and improved tolerability of PUR3100 compared to IV DHE.
  • We are currently pursuing options to advance PUR3100 into a Phase 2 clinical trial to investigate PUR3100 efficacy, safety, tolerability in treating acute migraine subjects."

Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?

Retrieved on: 
Thursday, August 17, 2023
Migraine, Roa, Moa, COVID-19, Perception, Prescription, CGRP, Launch, Neurology, DHE, Projection, RealTime, Dihydroergotamine, Patient, Physician, Mall of America, FDA, Impeller, Nasal spray, First Ever, Pfizer, Pharmaceutical industry, Ubrogepant

Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.

Key Points: 
  • Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.
  • As of June, over three-quarters of physicians planned to prescribe Zavzpret to their migraine patients within the first six months of availability.
  • One way to tease apart the relative advantages and disadvantages of new migraine therapies is to utilize Spherix’s Launch Dynamix™: Zavzpret series.
  • Spherix will be tracking the awareness and perception of these investigational, pipeline therapies in its separate service, RealTime Dynamix™.

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

Retrieved on: 
Thursday, June 15, 2023
Abstract, User experience, JW Marriott Marquis Miami, Acute, AHS, DHE, JW Marriott Hotels, Dihydroergotamine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Migraine

DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting.

Key Points: 
  • DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting.
  • The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from Thursday, June 15 to Sunday, June 18, 2023.
  • Full abstracts are now available on the AHS website and will be published in the journal Headache®.
  • Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

Retrieved on: 
Thursday, June 15, 2023
Aurora, Pain disorder, Medical Affairs Bureau, Migraine, Cleveland Clinic, IMPL, Headache (journal), AHS, Research, Pharmacy, DHE, DSM-IV codes, Poster, Patient, Nausea, Cleveland, Bladelet (impeller), Headache, Sleep, GI, Safety, Pharmaceutical industry, Dihydroergotamine

SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will present new real-world data adding to the growing body of evidence supporting Trudhesa® (dihydroergotamine mesylate [DHE]) nasal spray (0.725 mg per spray) as an effective acute therapy for migraine management. The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.

Key Points: 
  • The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.
  • Importantly, an increase in antinausea medications was not observed following Trudhesa use, whereas these medications are commonly used with DHE administered intravenously.
  • “DHE has an established safety and efficacy profile, often providing long-lasting relief for even the toughest of migraine attacks.
  • However, until Trudhesa, nasal delivery options couldn’t reach the upper nasal space, where DHE can be rapidly absorbed,” said Zubair Ahmed, M.D., a headache specialist and neurologist at the Cleveland Clinic.

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Retrieved on: 
Thursday, June 15, 2023
Ph2, Tmax, Partnership, IV, Safety, Pharmacokinetics, Cmax, DHE, Migraine, Patient, AUC, Poster, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Tolerability

The poster showcases data from the Phase 1 study of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine in 26 subjects, ages 18-49 years.

Key Points: 
  • The poster showcases data from the Phase 1 study of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine in 26 subjects, ages 18-49 years.
  • PUR3100 was generally well tolerated with fewer TEAEs in PUR3100-treated groups than in the IV DHE-treated group.
  • The Phase 2 study would assess the safety and effectiveness of two dose levels of PUR3100.
  • Pulmatrix is exploring partnership opportunities as a potential path forward for the Ph2 study."

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

Retrieved on: 
Thursday, May 18, 2023
Migraine, International Headache Society, NDA, DHE, Pain, Vomiting, Plasma, Nausea, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, TSE, Pharmaceutical industry

(Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.

Key Points: 
  • (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.
  • Although not required for approval based on Satsuma’s communications with the FDA, results from the 1,600-subject STS101 SUMMIT Phase 3 double-blind, placebo-controlled efficacy trial are also included in the NDA.
  • Satsuma announced topline SUMMIT trial results in November 2022 and subsequently announced further results in December 2022 .
  • The CVR is based on cumulative proceeds received by SNBL from the Monetization Event after making certain deductions.